EP1206670B1 - Lyophilization method - Google Patents
Lyophilization method Download PDFInfo
- Publication number
- EP1206670B1 EP1206670B1 EP00954556A EP00954556A EP1206670B1 EP 1206670 B1 EP1206670 B1 EP 1206670B1 EP 00954556 A EP00954556 A EP 00954556A EP 00954556 A EP00954556 A EP 00954556A EP 1206670 B1 EP1206670 B1 EP 1206670B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- drying
- temperature
- phase
- solvent
- pressure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title claims description 46
- 238000004108 freeze drying Methods 0.000 title claims description 34
- 238000001035 drying Methods 0.000 claims description 47
- 238000002360 preparation method Methods 0.000 claims description 35
- 239000002904 solvent Substances 0.000 claims description 31
- 238000002425 crystallisation Methods 0.000 claims description 20
- 230000008025 crystallization Effects 0.000 claims description 20
- 239000000243 solution Substances 0.000 claims description 12
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 11
- 229930195725 Mannitol Natural products 0.000 claims description 11
- 239000000594 mannitol Substances 0.000 claims description 11
- 235000010355 mannitol Nutrition 0.000 claims description 11
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 10
- 238000001816 cooling Methods 0.000 claims description 10
- 238000000859 sublimation Methods 0.000 claims description 10
- 230000008022 sublimation Effects 0.000 claims description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 7
- 238000005496 tempering Methods 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 230000009467 reduction Effects 0.000 claims description 6
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 5
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 5
- 229930006000 Sucrose Natural products 0.000 claims description 5
- 239000004471 Glycine Substances 0.000 claims description 4
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 4
- 230000009477 glass transition Effects 0.000 claims description 4
- 230000008023 solidification Effects 0.000 claims description 4
- 238000007711 solidification Methods 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 230000008014 freezing Effects 0.000 description 29
- 238000007710 freezing Methods 0.000 description 29
- 230000008569 process Effects 0.000 description 20
- 238000000137 annealing Methods 0.000 description 11
- 239000007787 solid Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000000463 material Substances 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 229960004793 sucrose Drugs 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 235000019426 modified starch Nutrition 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 238000003109 Karl Fischer titration Methods 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- XPTCDNRQXYTORI-UHFFFAOYSA-K calcium;sodium;carbonate;chloride Chemical compound [Na+].[Cl-].[Ca+2].[O-]C([O-])=O XPTCDNRQXYTORI-UHFFFAOYSA-K 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- -1 compounds amino acids Chemical class 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 125000003071 maltose group Chemical group 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000007669 thermal treatment Methods 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F26—DRYING
- F26B—DRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
- F26B5/00—Drying solid materials or objects by processes not involving the application of heat
- F26B5/04—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum
- F26B5/06—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum the process involving freezing
Definitions
- the present invention relates to a novel process for freeze-drying (Lyophilization).
- Freeze-drying is an important stabilization process hydrolysis-sensitive and thermolabile preparations, as well as materials of biological origin, which are dried under mild conditions should. With the help of freeze-drying materials can be used without major Changes and losses of biological activity are dried.
- One positive aspect of freeze-drying is that the dried, "lyophilic" Products due to their porous structure and very large specific surface area are very quickly reconstituted and their original properties in solution accept again. Therefore, freeze drying is preferred therapeutic sera, blood products, biologically active substances (hormones, Vitamins, enzymes, medicines), food preparations and flavorings.
- Freeze-drying liquid and semi-solid water-containing preparations are suitable, e.g. Solutions, emulsions and suspensions.
- the two drying steps differ in principle: In the Primary drying (primary drying) is the sublimation of the frozen Solvent under reduced pressure. At optional drying (Secondary drying), the evaporation of non-frozen solvent at reduced pressure and at elevated temperature.
- the method to be dried Preparations in containers, e.g. so-called vials, frozen at atmospheric pressure and The temperature of the product is set to one for the start of the main drying appropriate value set.
- the freezing is followed by the main drying, in which, under reduced pressure, the frozen solvent is transferred from the solid to the gaseous state, ie sublimed.
- the energy that is consumed in the sublimation is replenished, for example, via heatable control panels.
- the frozen preparation must not heat above its melting point.
- the main drying can be followed by a final drying, in which non-frozen solvent is removed at elevated temperature and reduced pressure.
- non-frozen solvent is removed at elevated temperature and reduced pressure.
- the temperature profile during the freeze-drying can be controlled by suitable devices.
- temperature-controlled control panels are known to those skilled in the art. In this process, the control panels can be brought to the desired glass transition temperature both after loading (cooling variant A) and before loading (cooling variant B). It is also possible to pre-temper the plates and / or the preparation on the plates to a temperature above the actual glass transition temperature to ensure a temperature equalization of the individual vials, or to minimize the cooling time to freezing. This is followed by the actual freezing with further lowering of the plate temperature (cooling variant C).
- the variants AC describe the freezing on shelves.
- Other known methods are freezing methods in cold baths and rotating vessels (shell freezing, spin freezing) or by spraying devices; they differ in principle from the methods described above.
- the preparations to be dried are aqueous systems.
- other solvents or mixtures thereof with aqueous systems can be used, such as carboxylic acids (eg glacial acetic acid), dimethyl sulfoxide (DMSO), ethers (eg dioxane), dimethylformamide or alcohols (eg t-butanol).
- US 3,233,333 describes a process for freeze-drying of meat and other foods that contain cellular structures, but by performing in four steps, the physical quality is not is impaired and taste, smell and texture practically remain unchanged.
- a tempering step thermal treatment or annealing
- This annealing step serves to crystallize amorphous solidified solids and not to require frozen solvent and thus increased crystallinity and to achieve a reduced residual moisture.
- Tg ' Glass transition temperature
- the amorphous phase which usually contains high levels of contains uncrystallized solvent, goes from the glass state in the rubbery Condition over and the mobility of molecules is increased. Consequence is the Formation of nucleoli that grow into crystals (so-called eruptive recrystallization) and the attachment of solvent molecules to existing ones Solvent crystals.
- the annealing process is also known from the literature. Descriptions of the tempering process can be found in The Lyophilization of Pharmaceuticals: A Literature Review, NA Williams and GP Polli, Journal of Parenteral Science and Technology, (1984 Mar-Apr) 38 (2) 48-59, Basic Aspects and Future Trends in the Freeze Drying of Pharmaceuticals , L. Rey, Develop. biol. Standard, Vol. 74, (Karger, Basel, 1991), pp. 3-8 and Fundamental Aspects of Lyophilization, L. Rey, Research and Development in Freeze-Drying, ed. By L. Rey, Paris, 1964, 24-47.
- Lyophilisates usually have a high flow resistance, which is the Escape of the gaseous solvent impeded.
- the consequences, the This may result in mechanical damage to the product cake by the escaping solvent vapor stream and thereby potential Product loss, as well as collapse and thawing phenomena during drying.
- by the end user especially to pharmaceutical and Food preparations also made aesthetic demands, so that strong Damage is not desired.
- An object of the present invention was therefore a process for freeze-drying to find, with which lyophilizates can be produced, which are the above do not exhibit said problematic properties and therefore easier are manageable.
- the fixed point of the preparation in the present application is the one Temperature understood in which the solvent in the preparation in the solid State of aggregation passes.
- This pressure reduction can e.g. be carried out at room temperature.
- the preparations are before or during the Lowering the pressure to a temperature between room temperature and the Fixed point of the preparation is, pre-tempered.
- This pre-tempering e.g. Stellplatten
- This pre-tempering further ensures that the cooling devices, the z.T. low Have cooling rates, in a short time to the desired crystallization temperature, i.e. can be brought into the range of the fixed point of the preparation. critical is that this Vortemper réelle not for the crystallization of the solvent leads.
- the pressure in the Drying chamber raised to ambient pressure and the temperature in the drying chamber for crystallization at or below the fixed point of Preparation (phase 2). It is also possible the pressure during to keep the crystallization reduced; this has no relevant effects the crystallization of the solvent.
- every crystallization is Temperature suitable, which is below the benchmark of the preparation or with him is identical.
- the temperature is Crystallization in aqueous solutions between -60 ° C and 0 ° C.
- the preparation is optionally to the final Temperature brought to the beginning of drying.
- This temperature is from the present product and the vapor pressure curve of the solvent from Pressure to be used in the main drying depends. In a preferred embodiment, this temperature is in aqueous solutions -60 ° C to 0 ° C.
- phase 4 a post-drying phase following the Main drying on.
- phase 4a an annealing phase
- an annealing process such as connected above. This annealing process is referred to as Phase 2a referred. Annealing provides products with higher crystallinity and lower residual moisture after the main drying and shortens the post-drying or makes them redundant.
- Fig. 2 shows a conventional manufacturing method of the prior art.
- FIG. 3 shows a conventional manufacturing process with annealing step after State of the art.
- phase 4 shows the method according to the invention with pressure reduction (phase 1), Crystallization (phase 2), annealing step (phase 2a) and subsequent main and Post-drying (phases 3 and 4).
- phase 5 shows the method according to the invention with pre-tempering and pressure reduction (Phase 1), crystallization (phase 2) and subsequent main and Post-drying (phases 3 and 4).
- Fig. 6 shows the inventive method with pre-tempering and Pressure reduction (phase 1), crystallization (phase 2), annealing step (phase 2a) and subsequent main and post-drying (phases 3 and 4).
- phase 7 shows the method according to the invention with pressure reduction (phase 1), Crystallization (phase 2), followed by main and post-drying (phases 3 and 4).
- the lyophilizates which can be prepared by the process according to the invention have a improved structure cohesion and are escaping from the Steam flow, even at increased sublimation rates, less mechanically strong damaged as lyophilisates by methods of the prior art getting produced. They show less pronounced collapse phenomena.
- Preparations with or without so-called scaffold formers are suitable for use in the process according to the invention.
- a porous scaffold or a matrix can be produced during freeze-drying.
- Freeze-drying products which are prepared using scaffold formers or other substances which are suitable as scaffolding agents on account of their physicochemical properties are preferred.
- Particularly preferred are freeze-drying products which are prepared using skeleton formers selected from the classes of compounds amino acids, carbohydrates (mono-, disaccharides, sugar alcohols, oligosaccharides, polysaccharides), peptides, polymeric compounds and salts.
- skeleton formers selected from the classes of compounds amino acids, carbohydrates (mono-, disaccharides, sugar alcohols, oligosaccharides, polysaccharides), peptides, polymeric compounds and salts.
- Most preferred are those prepared using frameworks selected from the group consisting of mannitol, sucrose, maltose, glycine and sodium chloride.
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Mechanical Engineering (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Preparation (AREA)
- Drying Of Solid Materials (AREA)
- Freezing, Cooling And Drying Of Foods (AREA)
Description
Die vorliegende Erfindung betrifft ein neues Verfahren zur Gefriertrocknung (Lyophilisation).The present invention relates to a novel process for freeze-drying (Lyophilization).
Die Gefriertrocknung ist ein wichtiges Verfahren zur Stabilisierung hydrolyseempfindlicher und thermolabiler Zubereitungen, sowie von Materialien biologischen Ursprungs, die unter schonenden Bedingungen getrocknet werden sollen. Mit Hilfe der Gefriertrocknung können Materialien ohne größere Veränderungen und Verluste an biologischer Aktivität getrocknet werden. Ein positiver Aspekt der Gefriertrocknung ist, daß die getrockneten, "lyophilen" Produkte aufgrund ihrer porösen Struktur und sehr großen spezifischen Oberfläche sehr schnell rekonstituierbar sind und ihre ursprünglichen Eigenschaften in Lösung wieder annehmen. Deshalb findet die Gefriertrocknung bevorzugt Anwendung bei therapeutischen Sera, Blutprodukten, biologisch aktiven Substanzen (Hormonen, Vitaminen, Enzymen, Arzneistoffen), Lebensmittelzubereitungen und Aromen. Zur Gefriertrocknung eignen sich flüssige und halbfeste wasserhaltige Zubereitungen, z.B. Lösungen, Emulsionen und Suspensionen.Freeze-drying is an important stabilization process hydrolysis-sensitive and thermolabile preparations, as well as materials of biological origin, which are dried under mild conditions should. With the help of freeze-drying materials can be used without major Changes and losses of biological activity are dried. One positive aspect of freeze-drying is that the dried, "lyophilic" Products due to their porous structure and very large specific surface area are very quickly reconstituted and their original properties in solution accept again. Therefore, freeze drying is preferred therapeutic sera, blood products, biologically active substances (hormones, Vitamins, enzymes, medicines), food preparations and flavorings. to Freeze-drying liquid and semi-solid water-containing preparations are suitable, e.g. Solutions, emulsions and suspensions.
Die Trocknung aus dem gefrorenen Zustand vereint die Vorteile von Einfrieren und Dehydratation bei niedriger Temperatur und wird im allgemeinen folgendermaßen durchgeführt:
- Abkühlung und Kristallisation des Lösungsmittels in der Zubereitung bei Atmosphärendruck.
- Haupttrocknung, d.h. Sublimation des kristallisierten Lösungsmittels.
- Nachtrocknung, d.h. Verdampfung von nicht kristallierten Lösungsmittelanteilen.
- Cooling and crystallization of the solvent in the preparation at atmospheric pressure.
- Main drying, ie sublimation of the crystallized solvent.
- Post-drying, ie evaporation of uncrystallized solvent fractions.
Die beiden Trocknungsschritte unterscheiden sich prinzipiell: Bei der Haupttrocknung (Primärtrocknung) erfolgt die Sublimation des gefrorenen Lösungsmittels unter vermindertem Druck. Bei der fakultativen Nachtrocknung (Sekundärtrocknung) erfolgt die Verdampfung von nicht-gefrorenem Lösungsmittel bei vermindertem Druck und bei erhöhter Temperatur.The two drying steps differ in principle: In the Primary drying (primary drying) is the sublimation of the frozen Solvent under reduced pressure. At optional drying (Secondary drying), the evaporation of non-frozen solvent at reduced pressure and at elevated temperature.
Bei den aus dem Stand der Technik bekannten Verfahren werden die zu trocknenden Zubereitungen in Gefäßen, z.B. sog. Vials, bei Atmosphärendruck eingefroren und die Temperatur des Produktes wird auf einen für den Start der Haupttrocknung geeigneten Wert eingestellt.In the known from the prior art, the method to be dried Preparations in containers, e.g. so-called vials, frozen at atmospheric pressure and The temperature of the product is set to one for the start of the main drying appropriate value set.
Auf das Einfrieren (Kristallisation) folgt die Haupttrocknung, bei der unter
reduziertem Druck das gefrorene Lösungsmittel vom festen in den gasförmigen
Aggregatzustand überführt, d.h. sublimiert wird. Die Energie, die bei der
Sublimation verbraucht wird, wird z.B. über beheizbare Stellplatten nachgeliefert.
Während der Haupttrocknung darf sich die gefrorene Zubereitung nicht über ihren
Schmelzpunkt erwärmen. An die Haupttrocknung kann sich eine Nachtrocknung
anschließen, bei der nicht-gefrorenes Lösungsmittel bei erhöhter Temperatur und
reduziertem Druck entfernt wird. Dabei handelt es sich um Lösungsmittel, das z.B.
an der Feststoffmatrix adsorbiert oder in amorphen Arealen eingeschlossen sein
kann.
Unter Kristallisation wird in der vorliegenden Anmeldung das Einfrieren (Erstarren)
des Lösungsmittelanteils in der Zubereitung verstanden. Unter Zubereitung wird in
der vorliegenden Anmeldung jede Art von Material verstanden, das sich für die
Gefriertrocknung eignet.The freezing (crystallization) is followed by the main drying, in which, under reduced pressure, the frozen solvent is transferred from the solid to the gaseous state, ie sublimed. The energy that is consumed in the sublimation is replenished, for example, via heatable control panels. During the main drying, the frozen preparation must not heat above its melting point. The main drying can be followed by a final drying, in which non-frozen solvent is removed at elevated temperature and reduced pressure. These are solvents which can be adsorbed on the solid matrix or enclosed in amorphous areas, for example.
Crystallization in the present application is understood as meaning the freezing (solidification) of the solvent fraction in the preparation. In the present application, preparation is understood to mean any type of material which is suitable for freeze-drying.
Der Temperaturverlauf während der Gefriertrocknung kann durch geeignete
Vorrichtungen gesteuert werden. Dem Fachmann bekannt sind insbesondere
temperierbare Stellplatten. Die Stellplatten können bei diesem Verfahren sowohl
nach dem Beladen (Abkühlvariante A), als auch vor dem Beladen auf die gewünschte
Einfriertemperatur gebracht werden (Abkühlvariante B). Möglich ist auch eine
Vortemperierung der Platten und/oder der Zubereitung auf den Platten auf eine
Temperatur oberhalb der eigentlichen Einfriertemperatur, um einen
Temperaturangleich der einzelnen Vials zu gewährleisten, bzw. um die Abkühlzeit
bis zum Einfrieren zu minimieren. Daran schließt sich das eigentliche Einfrieren mit
weiterer Absenkung der Plattentemperatur an (Abkühlvariante C).
Die Varianten A-C beschreiben das Einfrieren auf Stellplatten. Weitere bekannte
Verfahren sind Einfrierverfahren in Kältebädern und rotierenden Gefäßen (Shell
Freezing, Spin Freezing) oder durch Sprühvorrichtungen; sie unterscheiden sich
prinzipiell von den oben beschriebenen Verfahren.
Üblicherweise handelt es sich bei den zu trocknenden Zubereitungen um wässrige
Systeme. Prinzipiell sind auch andere Lösungsmittel oder deren Gemische mit
wässrigen Systemen einsetzbar, wie z.B. Carbonsäuren (z.B. Eisessig),
Dimethylsulfoxid (DMSO), Ether (z.B. Dioxan), Dimethylformamid oder Alkohole
(z.B. t-Butanol).The temperature profile during the freeze-drying can be controlled by suitable devices. In particular, temperature-controlled control panels are known to those skilled in the art. In this process, the control panels can be brought to the desired glass transition temperature both after loading (cooling variant A) and before loading (cooling variant B). It is also possible to pre-temper the plates and / or the preparation on the plates to a temperature above the actual glass transition temperature to ensure a temperature equalization of the individual vials, or to minimize the cooling time to freezing. This is followed by the actual freezing with further lowering of the plate temperature (cooling variant C).
The variants AC describe the freezing on shelves. Other known methods are freezing methods in cold baths and rotating vessels (shell freezing, spin freezing) or by spraying devices; they differ in principle from the methods described above.
Usually, the preparations to be dried are aqueous systems. In principle, other solvents or mixtures thereof with aqueous systems can be used, such as carboxylic acids (eg glacial acetic acid), dimethyl sulfoxide (DMSO), ethers (eg dioxane), dimethylformamide or alcohols (eg t-butanol).
Die verschiedenen, konventionellen Arten des Einfrierens und der Gefriertrocknung sind z.B. in einschlägigen Lehrbüchern hinlänglich beschrieben, so z.B. Lyophilisation, Essig, Oschmann, Wissenschaftliche Verlagsgesellschaft Stuttgart mbH, 1993; Seite 15-29, Gefriertrocknen, Georg-Wilhelm Oetjen, VCH Verlag, 1997; Seite 3-58 und Freeze Drying, Athanasios I. Liapis, in: Handbook of Industrial Drying, ed. by A.S. Mujumdar, Montreal, Seite 295-326. The various conventional types of freezing and freeze-drying are well described in relevant textbooks, such as lyophilization, vinegar, Oschmann, Scientific Verlagsgesellschaft Stuttgart mbH, 1993; Pages 15-29, freeze-drying, Georg-Wilhelm Oetjen, VCH Verlag, 1997; Page 3-58 and Freeze Drying, Athanasios I. Liapis, in: Handbook of Industrial Drying, ed. By AS Mujumdar, Montreal, pp. 295-326.
Darüber hinaus beschreibt US 3,233,333 ein Verfahren zur Gefriertrocknung von Fleisch und anderen Lebensmitteln, die zelluläre Strukturen enthalten, wobei durch eine Durchführung in vier Schritten die physische Qualität nicht beeinträchtigt wird und Geschmack, Geruch und Struktur praktisch unverändert bleiben. In addition, US 3,233,333 describes a process for freeze-drying of meat and other foods that contain cellular structures, but by performing in four steps, the physical quality is not is impaired and taste, smell and texture practically remain unchanged.
Allen Einfrierverfahren ist gemeinsam, daß bei Eignung der Zubereitung nach dem Einfrieren ein Temperschritt (Thermal Treatment oder Annealing) erfolgen kann. Dieser Temperschritt dient dazu, die Kristallisation von amorph erstarrten Feststoffen und nicht gefrorenem Lösungsmittel zu fordern und somit eine erhöhte Kristallinität sowie eine verminderte Restfeuchte zu erreichen. Zur Durchführung wird die gefrorene Zubereitung auf eine Temperatur erwärmt, die über der Glasübergangstemperatur (Tg') der amorph erstarrten Lösung und unter dem Schmelzpunkt der Lösung liegt. Die amorphe Phase, die in der Regel hohe Anteile an nicht kristallisiertem Lösungsmittel enthält, geht vom Glaszustand in den gummiartigen Zustand über und die Beweglichkeit von Molekülen wird erhöht. Folge ist die Bildung von Nukleoli, die zu Kristallen wachsen (sog. eruptive Rekristallisation) und die Anlagerung von Lösungsmittelmolkülen an bereits existierende Lösungsmittelkristalle.All freezing methods have in common that if the preparation is suitable for the Freezing a tempering step (thermal treatment or annealing) can be done. This annealing step serves to crystallize amorphous solidified solids and not to require frozen solvent and thus increased crystallinity and to achieve a reduced residual moisture. To carry out the frozen preparation heated to a temperature above that Glass transition temperature (Tg ') of the amorphous solidified solution and below the Melting point of the solution is. The amorphous phase, which usually contains high levels of contains uncrystallized solvent, goes from the glass state in the rubbery Condition over and the mobility of molecules is increased. Consequence is the Formation of nucleoli that grow into crystals (so-called eruptive recrystallization) and the attachment of solvent molecules to existing ones Solvent crystals.
Das Temperverfahren ist ebenfalls literaturbekannt. Beschreibungen des Temperverfahrens finden sich in The Lyophilization of Pharmaceuticals: A Literature Review, N.A. Williams and G. P. Polli, Journal of Parenteral Science and Technology, (1984 Mar-Apr) 38 (2) 48-59, Basic Aspects and Future Trends in the Freeze-Drying of Pharmaceuticals, L. Rey, Develop. biol. Standart., Vol. 74, (Karger, Basel, 1991), pp. 3-8 und Fundamental Aspects of Lyophilization, L. Rey, Researches and Development in Freeze-Drying, ed. by L. Rey, Paris, 1964, 24-47.The annealing process is also known from the literature. Descriptions of the tempering process can be found in The Lyophilization of Pharmaceuticals: A Literature Review, NA Williams and GP Polli, Journal of Parenteral Science and Technology, (1984 Mar-Apr) 38 (2) 48-59, Basic Aspects and Future Trends in the Freeze Drying of Pharmaceuticals , L. Rey, Develop. biol. Standard, Vol. 74, (Karger, Basel, 1991), pp. 3-8 and Fundamental Aspects of Lyophilization, L. Rey, Research and Development in Freeze-Drying, ed. By L. Rey, Paris, 1964, 24-47.
Die mit den Gefriertrocknungsverfahren nach dem Stand der Technik hergestellten Lyophilisate weisen meist einen hohen Strömungswiderstand auf, der das Entweichen des gasförmigen Lösungsmittels behindert. Zudem kann das Auskristallisieren der gelösten Inhaltsstoffe teilweise bis ganz unterbleiben, so daß Produkte erhalten werden, die teils bis ganz amorph vorliegen. Die Folgen, die daraus resultieren können, sind mechanische Beschädigung des Produktkuchens durch den entweichenden Lösungsmitteldampfstrom und dadurch potentieller Produktverlust, sowie Kollaps- und Auftauphänomene während der Trockung. Darüberhinaus werden vom Endverbraucher besonders an pharmazeutische und Lebensmittelzubereitungen auch ästhetische Anforderungen gestellt, so daß starke Beschädigungen nicht erwünscht sind.Those prepared by the prior art freeze-drying methods Lyophilisates usually have a high flow resistance, which is the Escape of the gaseous solvent impeded. In addition, that can Crystallize the dissolved ingredients partially to completely omit, so that Products are obtained, which are partly to completely amorphous. The consequences, the This may result in mechanical damage to the product cake by the escaping solvent vapor stream and thereby potential Product loss, as well as collapse and thawing phenomena during drying. In addition, by the end user especially to pharmaceutical and Food preparations also made aesthetic demands, so that strong Damage is not desired.
Eine Aufgabe der vorliegenden Erfindung war es deshalb, ein Verfahren zur Gefriertrocknung zu finden, mit dem sich Lyophilisate herstellen lassen, welche die oben genannten problematischen Eigenschaften nicht aufweisen und daher leichter handhabbar sind. An object of the present invention was therefore a process for freeze-drying to find, with which lyophilizates can be produced, which are the above do not exhibit said problematic properties and therefore easier are manageable.
Überraschenderweise wurde nun gefunden, daß man mechanisch stabilere Lyophilisate erhält, wenn man das Verfahren zur Gefriertrocknung folgendermaßen durchführt:
- Phase 1:
- Erniedrigen des Druckes in der Trocknungskammer bis zum Einsetzen einer sichtbaren Kristallisation des Lösungsmittels bei einer Temperatur in der Trocknungskammer, die oberhalb des Festpunktes der Zubereitung liegt.
- Phase 2:
- Erniedrigen der Temperatur in der Trocknungskammer auf eine Temperatur, die unter dem Festpunkt der Zubereitung liegt oder mit diesem identisch ist, bis zum Abschluß der Kristallisation des Lösungsmittels.
- Phase 3:
- Sublimation des gefrorenen Lösungsmittels mittels vermindertem Druck.
- Phase 1:
- Lowering the pressure in the drying chamber until onset of visible crystallization of the solvent at a temperature in the drying chamber that is above the fixed point of the preparation.
- Phase 2:
- Lowering the temperature in the drying chamber to a temperature below or equal to the melting point of the formulation until the crystallization of the solvent is completed.
- Phase 3:
- Sublimation of the frozen solvent by means of reduced pressure.
Unter dem Festpunkt der Zubereitung wird in der vorliegenden Anmeldung diejenige Temperatur verstanden, bei der das Lösungsmittel in der Zubereitung in den festen Aggregatzustand übergeht.The fixed point of the preparation in the present application is the one Temperature understood in which the solvent in the preparation in the solid State of aggregation passes.
Erfindungsgemäß wird der Druck in der Trocknungskammer anfänglich bei einer Temperatur in der Trocknungskammer, die oberhalb des Festpunktes der Zubereitung liegt, auf einen Druckwert unterhalb des Atmosphärendrucks (gemäß Fig. 1) reduziert. Dies hat eine oberflächliche Abkühlung der Zubereitung durch Verdampfung und eine partielle Kristallisation des Lösungsmittels an der Oberfläche zur Folge (Phase 1). In einer bevorzugten Ausführungsform beträgt der Druck hierbei bei wässrigen Lösungen 0,1 bis 6 mbar, insbesondere 0,2 bis 3 mbar. Für verschiedene Zubereitungen ist dieser Druck p in der Trocknungskammer (gemessen mit einem Kapazitätsmanometer) in Abhängigkeit von der Konzentration c (in mol/L) in Fig. 1 aufgetragen. Die Werte für verschiedene wässrige Zubereitungen wurde folgendermaßen dargestellt:
- durchgezogene Linie, Quadrate = Mannitol
- durchgezogene Linie, Kreise = Saccharose
- unterbrochene Linie, Rauten = Natriumchlorid
- unterbrochene Linie; Kreise = Glycin
- unterbrochene Linie, Dreiecke = Maltose
- Quadrat auf der Ordinate = Lösungsmittel Wasser
- solid line, squares = mannitol
- solid line, circles = sucrose
- broken line, diamonds = sodium chloride
- broken line; Circles = glycine
- broken line, triangles = maltose
- Square on the ordinate = solvent water
Diese Druckverminderung kann z.B. bei Raumtemperatur durchgeführt werden. In einer weiteren Ausführungsform werden die Zubereitungen vor oder während der Druckerniedrigung auf eine Temperatur, die zwischen Raumtemperatur und dem Festpunkt der Zubereitung liegt, vortemperiert. Diese Vortemperierung (z.B. auf Stellplatten) gewährleistet weiterhin, daß die Kühlvorrichtungen, die z.T. geringe Abkühlraten aufweisen, in kurzer Zeit auf die gewünschte Kristallisationstemperatur, d.h. in den Bereich des Festpunktes der Zubereitung gebracht werden können. Entscheidend ist, daß diese Vortemperierung nicht zur Kristallisation des Lösungsmittels führt.This pressure reduction can e.g. be carried out at room temperature. In In another embodiment, the preparations are before or during the Lowering the pressure to a temperature between room temperature and the Fixed point of the preparation is, pre-tempered. This pre-tempering (e.g. Stellplatten) further ensures that the cooling devices, the z.T. low Have cooling rates, in a short time to the desired crystallization temperature, i.e. can be brought into the range of the fixed point of the preparation. critical is that this Vortemperierung not for the crystallization of the solvent leads.
Haben sich nun Kristalle, z.B. in Form eines Wasser/Eis-Gemisches oder einer auf der Oberfläche schwimmenden Eisschicht gebildet, kann der Druck in der Trocknungskammer wieder auf Umgebungsdruck angehoben und die Temperatur in der Trocknungskammer zur Kristallisation auf oder unter den Festpunkt der Zubereitung gebracht werden (Phase 2). Es ist ebenso möglich, den Druck während der Kristallisation vermindert zu halten; dies hat keine relevanten Auswirkungen auf die Kristallisation des Lösungsmittels. Prinzipiell ist zur Kristallisation jede Temperatur geeignet, die unter dem Festpunkt der Zubereitung liegt oder mit ihm identisch ist. In einer bevorzugten Ausführungsform beträgt die Temperatur zur Kristallisation bei wässrigen Lösungen zwischen -60°C und 0°C.Have crystals, e.g. in the form of a water / ice mixture or on formed the surface floating ice layer, the pressure in the Drying chamber raised to ambient pressure and the temperature in the drying chamber for crystallization at or below the fixed point of Preparation (phase 2). It is also possible the pressure during to keep the crystallization reduced; this has no relevant effects the crystallization of the solvent. In principle, every crystallization is Temperature suitable, which is below the benchmark of the preparation or with him is identical. In a preferred embodiment, the temperature is Crystallization in aqueous solutions between -60 ° C and 0 ° C.
Nach der Kristallisation wird die Zubereitung gegebenenfalls auf die endgültige Temperatur zum Beginn der Trocknung gebracht. Diese Temperatur ist dabei vom vorliegenden Produkt und über die Dampfdruckkurve des Lösungsmittels vom Druck, der in der Haupttrocknung verwendet werden soll, abhängig. In einer bevorzugten Ausführungsform beträgt diese Temperatur bei wässrigen Lösungen -60°C bis 0°C.After crystallization, the preparation is optionally to the final Temperature brought to the beginning of drying. This temperature is from the present product and the vapor pressure curve of the solvent from Pressure to be used in the main drying depends. In a preferred embodiment, this temperature is in aqueous solutions -60 ° C to 0 ° C.
Danach schließt sich die Haupttrocknung an. Diese verläuft prinzipiell wie bei den
Verfahren nach dem Stand der Technik. Bei einer weiteren Ausführungsform weist
das Verfahren zusätzlich eine Nachtrocknungsphase (Phase 4) im Anschluß an die
Haupttrocknung auf. Diese ist aber bei Vorliegen einer Temperphase (Phase 2a) in
einigen Fällen nicht nötig.Then the main drying follows. This runs in principle as with the
Method according to the prior art. In a further embodiment has
the process additionally a post-drying phase (phase 4) following the
Main drying on. However, this is in the presence of an annealing phase (
Gemäß einer weiteren Ausführungsform wird an Phase 2 ein Temperverfahren wie
oben beschrieben angeschlossen. Dieses Temperverfahren wird im folgenden als
Phase 2a bezeichnet. Das Tempern liefert Produkte mit höherer Kristallinität und
niedrigerer Restfeuchte nach der Haupttrocknung und verkürzt die Nachtrocknung
bzw. macht sie überflüssig.According to another embodiment, an annealing process such as
connected above. This annealing process is referred to as
Das erfindungsgemäße Verfahren soll durch die Figuren 2 bis 7 genauer erläutert werden: Hierbei sind die Temperatur (T) und der Druck (p) in Millibar (mbar) in der Trocknungskammer gegen die Zeit t aufgetragen, wobei die Temperatur als durchgezogene, der Druck als unterbrochene Linie dargestellt ist. Zur besseren Verdeutlichung der Verfahren zeigen die Figuren stets Ausführungsformen mit Haupt- und Nachtrocknung.The inventive method will be explained in more detail by the figures 2 to 7 Here are the temperature (T) and the pressure (p) in millibars (mbar) in the Drying chamber applied against the time t, with the temperature as solid, the pressure is shown as a broken line. For better Clarification of the method, the figures always show embodiments Main and post-drying.
Fig. 2 zeigt ein herkömmliches Herstellungsverfahren nach dem Stand der Technik.Fig. 2 shows a conventional manufacturing method of the prior art.
Fig. 3 zeigt ein herkömmliches Herstellungsverfahren mit Temperschritt nach dem Stand der Technik.FIG. 3 shows a conventional manufacturing process with annealing step after State of the art.
Fig. 4 zeigt das erfindungsgemäße Verfahren mit Druckverminderung (Phase 1),
Kristallisation (Phase 2), Temperschritt (Phase 2a) und anschließender Haupt- und
Nachtrocknung (Phasen 3 und 4). 4 shows the method according to the invention with pressure reduction (phase 1),
Crystallization (phase 2), annealing step (
Fig. 5 zeigt das erfindungsgemäße Verfahren mit Vortemperierung und Druckverminderung (Phase 1), Kristallisation (Phase 2) und anschließender Haupt- und Nachtrocknung (Phasen 3 und 4).5 shows the method according to the invention with pre-tempering and pressure reduction (Phase 1), crystallization (phase 2) and subsequent main and Post-drying (phases 3 and 4).
Fig. 6 zeigt das erfindungsgemäße Verfahren mit Vortemperierung und
Druckverminderung (Phase 1), Kristallisation (Phase 2), Temperschritt (Phase 2a)
und anschließender Haupt- und Nachtrocknung (Phasen 3 und 4).Fig. 6 shows the inventive method with pre-tempering and
Pressure reduction (phase 1), crystallization (phase 2), annealing step (
Fig. 7 zeigt das erfindungsgemäße Verfahren mit Druckverminderung (Phase 1), Kristallisation (Phase 2), und anschließender Haupt- und Nachtrocknung (Phasen 3 und 4).7 shows the method according to the invention with pressure reduction (phase 1), Crystallization (phase 2), followed by main and post-drying (phases 3 and 4).
Die mit dem erfindungsgemäßen Verfahren herstellbaren Lyophilisate weisen einen verbesserten Strukturzusammenhalt auf und werden vom entweichenden Dampfstrom, auch bei erhöhten Sublimationsraten, weniger stark mechanisch beschädigt als Lyophilisate, die durch Verfahren nach dem Stand der Technik hergestellt werden. Sie zeigen weniger ausgeprägte Kollapsphänomene.The lyophilizates which can be prepared by the process according to the invention have a improved structure cohesion and are escaping from the Steam flow, even at increased sublimation rates, less mechanically strong damaged as lyophilisates by methods of the prior art getting produced. They show less pronounced collapse phenomena.
Die nach dem erfindungsgemäßen Verfahren erzielbaren Restfeuchtegehalte sind prinzipiell mit denjenigen vergleichbar, die durch Gefriertrocknung nach dem Stand der Technik erzielt werden (siehe Tab. 3)The residual moisture contents which can be achieved by the process according to the invention are in principle comparable to those obtained by freeze-drying to the state technology can be achieved (see Tab. 3)
Zur Verwendung im erfindungsgemäßen Verfahren eignen sich Zubereitungen mit
oder ohne sogenannte Gerüstbildner. Mit solchen Gerüstbildnern kann bei der
Gefriertrocknung ein poröses Gerüst bzw. eine Matrix erzeugt werden. Bevorzugt
sind Gefriertrocknungsprodukte, die unter Verwendung von Gerüstbildnern bzw.
anderen Substanzen, die aufgrund ihrer physikalisch-chemischen Eigenschaften als
Gerüstbildner geeignet sind, hergestellt werden. Besonders bevorzugt sind Gefriertrocknungsprodukte,
die unter Verwendung von Gerüstbildnern ausgewählt aus den
Verbindungsklassen Aminosäuren, Kohlenhydrate (Mono-, Disaccharide, Zuckeralkohole,
Oligo-, Polysaccharide), Peptide, polymere Verbindungen und Salze hergestellt
werden. Am meisten bevorzugt sind solche, die unter Verwendung von Gerüstbildnem
ausgewählt aus der Gruppe Mannitol, Saccharose, Maltose, Glycin und
Natriumchlorid hergestellt werden.
Für das erfindungsgemäße Verfahren kommt eine Vielzahl von Lösungsmitteln in Frage. Des besseren Verständnisses halber werden in der Beschreibung überwiegend wäßrige Systeme behandelt. Die Erfindung betrifft aber ausdrücklich auch nichtwäßrige Systeme. Bevorzugt werden wäßrige Lösungen eingesetzt. For the process according to the invention, a multiplicity of solvents are used Question. For the sake of better understanding, the description will be overwhelming treated aqueous systems. However, the invention also relates expressly nonaqueous systems. Preference is given to using aqueous solutions.
- Es wurde eine 5%-ige,wäßrige Lösung von Mannitol hergestellt und über ein 0,2µm Membranfilter sterilfiltriert.There was prepared a 5% aqueous solution of mannitol and a 0.2μm membrane filter sterile filtered.
- Die Lösung wurde zu 3ml in 10R-Röhrenglasvials abgefüllt und Gefriertrocknungsstopfen aufgesetzt.The solution was filled to 3 ml in 10R tube glass vials and lyophilization stoppers placed.
- Für die Gefriertrocknung wurden die befüllten Vials in einen Gefriertrockner der Fa. Kniese (Stellfläche 0,6 m2) verbracht.For the freeze-drying, the filled vials were placed in a freeze drier of the company Kniese (footprint 0.6 m 2 ).
- Die Lösung wurden auf den Stellplatten bei +10°C vortemperiert.The solution was pre-tempered on the control plates at + 10 ° C.
- Danach wurde der Kammerdruck auf 0,65 mbar erniedrigt (Parameterwahl siehe Fig. 1).Thereafter, the chamber pressure was lowered to 0.65 mbar (for parameter selection see Fig. 1).
- Nach Erreichen des Druckwertes von 0,65 mbar und Einsetzen des partiellen Einfrierens an der Produktoberfläche, wurde auf Umgebungsdruck belüftet und gleichzeitig die Stellplatten auf eine Temperatur gebracht, die z.B. für Mannitol -7,5°C betragen kann.After reaching the pressure value of 0.65 mbar and inserting the partial Freezing at the product surface was vented to ambient pressure and at the same time bringing the control panels to a temperature e.g. for mannitol May be -7.5 ° C.
- Die Produkte wurden jeweils 1 Stunde bei der jeweiligen Temperatur gehalten und anschließend auf -40°C abgekühlt (Einfriervariante III).The products were each held at the respective temperature for 1 hour and then cooled to -40 ° C (freezing variant III).
- An das Einfrieren schloß sich eine Haupttrocknung über 8 Stunden bei +40°C und 1,6 mbar ohne Nachtrocknung an. Die beobachteten Auffälligkeiten wurden in Tab. 2 angegeben.The freezing was followed by a main drying for 8 hours at + 40 ° C and 1.6 mbar without drying. The observed abnormalities were in Tab. 2.
- Als Referenz wurden entsprechende Lösungen herangezogen, die nicht dem "erfindungsgemäßen" vakuum-induziertem Einfrieren (Einfriervariante III) unterworfen wurden, sondern mit 2K/min auf -40°C (Einfriervariante I) und auftretender Unterkühlung eingefroren bzw. im Kältebad schnell auf -60°C (Einfriervariante II) eingefroren und dann unter gleichen Bedingungen gefriergetrocknet wurden.As a reference, appropriate solutions were used which did not correspond to the subjected to vacuum-induced freezing (freezing variant III) according to the invention but with 2K / min to -40 ° C (freezing variant I) and occurring Frozen undercooling or fast in the cold bath to -60 ° C (freezing variant II) and then lyophilized under the same conditions were.
- Es wurde eine wäßrige, 2%-ige Lösung von Mannitol hergestellt und über ein 0,2µm Membranfilter sterilfiltriert. It was prepared an aqueous, 2% solution of mannitol and a 0.2μm membrane filter sterile filtered.
- Die Lösung wurde zu 3 ml in 10R- Röhrenglasvials abgefüllt und Gefriertrocknungsstopfen aufgesetzt.The solution was filled to 3 ml in 10R tube glass vials and lyophilization stoppers placed.
- Für die Gefriertrocknung wurden die Vials in einen Gefriertrockner der Fa. Kniese (Stellfläche 0,6 m2) verbracht.For freeze-drying, the vials were placed in a freeze drier from the company Kniese (footprint 0.6 m 2 ).
- Die Lösungen wurden auf den Stellplatten bei +10°C vortemperiert.The solutions were pre-tempered on the control plates at + 10 ° C.
- Danach wurde der Kammerdruck auf 0,65 mbar erniedrigt (Parameterwahl siehe Fig. 1).Thereafter, the chamber pressure was lowered to 0.65 mbar (for parameter selection see Fig. 1).
- Nach Erreichen des Druckwertes von 0,65 mbar und Einsetzen des partiellen Einfrierens an der Produktoberfläche, wurde auf Umgebungsdruck belüftet und gleichzeitig die Stellplatten auf eine Temperatur gebracht, die z.B. für Mannitol -7,5°C betragen kann.After reaching the pressure value of 0.65 mbar and inserting the partial Freezing at the product surface was vented to ambient pressure and at the same time bringing the control panels to a temperature e.g. for mannitol May be -7.5 ° C.
- Die Produkte wurden jeweils 1 Stunde bei der jeweiligen Temperatur gehalten und anschließend auf -40°C abgekühlt (Variante III).The products were each held at the respective temperature for 1 hour and then cooled to -40 ° C (variant III).
- Für Variante IV wurden die Proben Proben im Anschluß an das Prozedere von Variante III auf -3°C erwärmt, 4 Stunden bei dieser Temperatur getempert und anschließend auf -40°C abgekühlt.For variant IV, samples were taken following the procedure of Variant III heated to -3 ° C, annealed at this temperature for 4 hours and then cooled to -40 ° C.
- Als Referenz wurden Proben mit einer Abkühlrate von 2 K/min auf -40 eingefroren. Die Proben unterkühlten dabei. (Variante I).As a reference, samples were frozen to -40 at a cooling rate of 2 K / min. The samples undercooled. (Variant I).
- An das Einfrieren nach Variante I, III oder IV, schloß sich eine Haupttrocknung über 20 Stunden bei -10°C und 0,2 mbar und eine Nachtrocknung bei +40°C und 0,2 mbar über 2 Stunden an.On freezing to variant I, III or IV, followed by a main drying over 20 hours at -10 ° C and 0.2 mbar and a final drying at + 40 ° C and 0.2 mbar for 2 hours.
Nach der Gefriertrocknung wurde zusätzlich noch die Restfeuchte der Lyophilisate
durch eine Karl-Fischer-Titration bestimmt:
Claims (9)
- Method for freeze-drying preparations in a drying chamber comprising the steps cooling the preparation and crystallizing the solvent and sublimation of the frozen solvent by means of reduced pressure, in which the method is carried out as follows:
- phase 1:
- reducing the pressure in the drying chamber until the onset of a visible crystallization of the solvent at a temperature in the drying chamber which is above the solidification point of the preparation,
- phase 2:
- reduction of the temperature in the drying chamber to a temperature which is below the solidification point of the preparation or is identical to this, until completion of crystallization of the solvent,
- phase 3:
- sublimation of the frozen solvent by means of reduced pressure.
- Method according to Claim 1, characterized in that an aqueous solution is present.
- Method according to Claim 1, characterized in that the pressure in phase 1 is reduced to 0.1 to 6 mbar in the case of aqueous preparations.
- Method according to Claim 3, characterized in that the pressure in phase 1 is reduced to 0.2 to 3 mbar.
- Method according to Claim 1, characterized in that the temperature in phase 2 is set to -60 to 0°C in the case of aqueous preparations.
- Method according to Claim 1, characterized in that a tempering step (phase 2a) is carried out, in which a temperature is set which is above the glass transition temperature (Tg') of the amorphously solidified solution and below the solidification point of the preparation.
- Method according to Claim 1, characterized in that the temperature at the start of the primary drying is set to -60 to 0°C in the case of aqueous preparations.
- Method according to Claim 1, characterized in that a cake-forming agent is used.
- Method according to Claim 1, characterized in that the cake-forming agent is mannitol, sucrose, maltose, glycine or sodium chloride.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19936281A DE19936281C2 (en) | 1999-08-02 | 1999-08-02 | Freeze-drying process |
| DE19936281 | 1999-08-02 | ||
| PCT/EP2000/007034 WO2001009559A1 (en) | 1999-08-02 | 2000-07-21 | Lyophilization method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP1206670A1 EP1206670A1 (en) | 2002-05-22 |
| EP1206670B1 true EP1206670B1 (en) | 2005-02-09 |
Family
ID=7916878
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP00954556A Expired - Lifetime EP1206670B1 (en) | 1999-08-02 | 2000-07-21 | Lyophilization method |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6684524B1 (en) |
| EP (1) | EP1206670B1 (en) |
| JP (1) | JP2003506654A (en) |
| AU (1) | AU6697200A (en) |
| CA (1) | CA2380949A1 (en) |
| DE (2) | DE19936281C2 (en) |
| ES (1) | ES2237445T3 (en) |
| WO (1) | WO2001009559A1 (en) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10058119A1 (en) | 2000-11-22 | 2002-05-23 | Bayer Ag | Pharmaceutical kit containing repinotan, for use in acute treatment of neurological disorders such as stroke, including assay composition for determining body repinotan levels to optimize dosage |
| FR2836482B1 (en) * | 2002-02-25 | 2005-02-11 | Zedrys Zeolite Drying System | METHOD AND FACILITIES FOR OBTAINING LIVE DESSECHED CELLS |
| EP1648454A1 (en) * | 2003-07-25 | 2006-04-26 | Wyeth | Cci-779 lyophilized formulations |
| US9453675B2 (en) * | 2006-02-10 | 2016-09-27 | Sp Industries, Inc. | Method of inducing nucleation of a material |
| US8794013B2 (en) | 2006-02-10 | 2014-08-05 | Praxair Technology, Inc. | Method and system for nucleation control in a controlled rate freezer (CRF) |
| US8793895B2 (en) * | 2006-02-10 | 2014-08-05 | Praxair Technology, Inc. | Lyophilization system and method |
| US8820097B2 (en) | 2006-02-10 | 2014-09-02 | Praxair, Technology, Inc. | Method and system for regulating the mixture of cryogen liquid and warm gas for a controlled rate cryogenic chiller or freezing system |
| EP1870649A1 (en) | 2006-06-20 | 2007-12-26 | Octapharma AG | Lyophilisation targetting defined residual moisture by limited desorption energy levels |
| CA2665902A1 (en) * | 2006-10-03 | 2008-04-10 | Wyeth | Lyophilization methods and apparatuses |
| US8240065B2 (en) | 2007-02-05 | 2012-08-14 | Praxair Technology, Inc. | Freeze-dryer and method of controlling the same |
| FR2923823B1 (en) * | 2007-11-21 | 2010-10-08 | Centre Nat Rech Scient | AEROGELS OF CARBON NANOTUBES |
| CA2736317C (en) * | 2008-09-12 | 2015-06-16 | Enwave Corporation | Apparatus and method for dehydrating biological materials with freezing and microwaving |
| CN101718485B (en) * | 2009-11-25 | 2013-02-06 | 天津商业大学 | Equipment for methods of drying or concentrating near freezing temperatures |
| WO2011067780A1 (en) | 2009-12-02 | 2011-06-09 | Central Pollution Control Board | An apparatus and method of preservation of animal skins/ hides |
| US8549768B2 (en) * | 2011-03-11 | 2013-10-08 | Linde Aktiengesellschaft | Methods for freeze drying |
| RU2480520C1 (en) * | 2011-10-03 | 2013-04-27 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования Воронежская государственная технологическая академия (ФГБОУ ВПО ВГТА) | Method of controlling processes of obtaining and drying enzyme preparations |
| IN2013MU01127A (en) | 2013-03-26 | 2015-05-01 | Astron Res Ltd | |
| CN104697298B (en) * | 2015-03-13 | 2016-12-07 | 湖南科伦制药有限公司 | A kind of lyophilizing technique of water soluble vitamins |
| CN108699593A (en) | 2016-02-05 | 2018-10-23 | 简·探针公司 | Dry Amplification object |
| DE102016215844B4 (en) | 2016-08-23 | 2018-03-29 | OPTIMA pharma GmbH | Method and apparatus for freeze drying |
| DE112018002597B4 (en) | 2017-05-19 | 2024-05-02 | Gen-Probe Incorporated | DRIED COMPOSITIONS CONTAINING FLAP ENDONUCLEASE |
| DE102017217415B4 (en) | 2017-09-29 | 2022-11-10 | OPTIMA pharma GmbH | Process and device for freeze drying |
| EP3856346A1 (en) | 2018-09-26 | 2021-08-04 | medac Gesellschaft für klinische Spezialpräparate mbH | Crystalline form of treosulfan |
| ES2964602T3 (en) | 2018-09-26 | 2024-04-08 | Medac Ges Fuer Klinische Spezialpraeparate Mbh | Treosulfan lyophilisate |
| US11744257B1 (en) * | 2018-10-19 | 2023-09-05 | Harvest Right, LLC | Freeze-drying methods including vacuum freezing |
| US12225914B1 (en) | 2023-05-08 | 2025-02-18 | Harvest Right, LLC | Freeze dryers and drying processes for materials with low water content |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3233333A (en) * | 1962-06-01 | 1966-02-08 | Oppenheimer Franz | Method of freeze drying food products |
| US4520574A (en) | 1983-02-25 | 1985-06-04 | House Food Industrial Co., Ltd. | Process for drying foods under reduced pressure |
| JPS6098939A (en) * | 1983-11-04 | 1985-06-01 | Sutefuano Shokai:Kk | Dried meat production equipment that can be regenerated into fresh meat |
| JPH02306088A (en) * | 1989-05-18 | 1990-12-19 | Fujitsu Ltd | Freeze drying vessel |
| US5199187A (en) * | 1991-07-31 | 1993-04-06 | Sp Industries | Freeze dryer apparatus having an interim condensing system and use thereof |
| NZ279549A (en) * | 1994-02-09 | 1996-11-26 | Kinerton Ltd | Obtaining solid material by drying a solution thereof, supercooled spray of solution expanded into vacuum and frozen droplets collected |
| AU4658296A (en) * | 1995-01-20 | 1996-08-07 | Freezedry Specialties, Inc. | Freeze dryer |
| US5687490A (en) * | 1996-08-01 | 1997-11-18 | Harrison; Jack B. | Method of drying lumber |
| US5996248A (en) * | 1996-09-19 | 1999-12-07 | The Boc Group, Inc. | Freeze drying method |
| DE19719398A1 (en) * | 1997-05-07 | 1998-11-12 | Amsco Finn Aqua Gmbh | Process for controlling a freeze-drying process |
| US5948144A (en) * | 1997-10-07 | 1999-09-07 | Genetics Institute, Inc. | Lyophilizer system |
| CA2303786A1 (en) * | 1998-07-14 | 2000-01-27 | Toray Industries, Inc. | Freeze-dried product and method for preparing the same |
| US20020124431A1 (en) * | 1999-08-27 | 2002-09-12 | Patrick Duhaut | Method for drying substances and/or preserving dryness by means of a semipermeable membrane |
| US6643950B2 (en) * | 2000-12-06 | 2003-11-11 | Eisai Co., Ltd. | System and method for measuring freeze dried cake resistance |
-
1999
- 1999-08-02 DE DE19936281A patent/DE19936281C2/en not_active Expired - Fee Related
-
2000
- 2000-07-21 WO PCT/EP2000/007034 patent/WO2001009559A1/en not_active Ceased
- 2000-07-21 ES ES00954556T patent/ES2237445T3/en not_active Expired - Lifetime
- 2000-07-21 JP JP2001513796A patent/JP2003506654A/en active Pending
- 2000-07-21 EP EP00954556A patent/EP1206670B1/en not_active Expired - Lifetime
- 2000-07-21 US US10/048,783 patent/US6684524B1/en not_active Expired - Fee Related
- 2000-07-21 AU AU66972/00A patent/AU6697200A/en not_active Abandoned
- 2000-07-21 CA CA002380949A patent/CA2380949A1/en not_active Abandoned
- 2000-07-21 DE DE50009496T patent/DE50009496D1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2003506654A (en) | 2003-02-18 |
| DE19936281A1 (en) | 2001-02-15 |
| DE19936281C2 (en) | 2002-04-04 |
| DE50009496D1 (en) | 2005-03-17 |
| ES2237445T3 (en) | 2005-08-01 |
| EP1206670A1 (en) | 2002-05-22 |
| AU6697200A (en) | 2001-02-19 |
| WO2001009559A1 (en) | 2001-02-08 |
| US6684524B1 (en) | 2004-02-03 |
| CA2380949A1 (en) | 2001-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1206670B1 (en) | Lyophilization method | |
| DE60035125T2 (en) | PRESERVATION OF SENSITIVE BIOLOGICAL MATERIAL | |
| DE69033874T2 (en) | Process for the preparation of drug-containing freeze-dried formulations | |
| DE69129253T2 (en) | Method and device for cryopreparation, dry stabilization and rehydration of suspensions of cells | |
| EP1032799B1 (en) | Method for producing porous structures | |
| Sellers et al. | Dry powders of stable protein formulations from aqueous solutions prepared using supercritical CO2‐assisted aerosolization | |
| DE2520173C3 (en) | Process for the preparation of glucopyranosido-1,6-mannitol and its use as a sugar substitute | |
| DE3789401T2 (en) | Biological cryoprotection. | |
| DE2614668C2 (en) | Process for the production of sterile, crystalline cefalotin sodium, cefaloridin betaine or cefazolin sodium | |
| DE2752443C2 (en) | Process for the production of cefazolin sodium | |
| DE60001744T2 (en) | STABILIZER FOR MEDICINAL PRODUCTS | |
| DE2747802A1 (en) | METHOD FOR EVAPORATING AND SPRAYING DRYING A SACCHAROSE SOLUTION AND SYSTEM FOR EXERCISING THE METHOD | |
| DE3628468A1 (en) | NEW APPLICATION FORM (ALPHA) INTERFERONE | |
| DE2243014A1 (en) | LYOPHILIZED SERUM OR PLASMA AND METHOD FOR PREPARING IT | |
| EP1146863B1 (en) | Lyophilisates with improved reconstitutibility | |
| DE3601922A1 (en) | STABILIZED VIRUS ANTIGUE, METHOD FOR PRODUCING IT AND ITS USE | |
| DE2849963C2 (en) | ||
| JPS6168412A (en) | Freeze-drying of medicine | |
| EP1773778A1 (en) | Method for the preparation of crystal forms of torsemide in a pure state | |
| JP2988631B2 (en) | Lyophilized preparation of fosfomycin sodium and method for producing the same | |
| EP2732811B1 (en) | Method for producing a freeze-dried compound | |
| CN115581675B (en) | Preparation method of clindamycin phosphate for injection | |
| AT398763B (en) | METHOD FOR INSULATING A PURE, WHITE CAFFEINE | |
| US20040007689A1 (en) | Process for controlling the hydrate mix of a compound | |
| DE2752442C2 (en) | Process for the production of crystalline cefalotin sodium |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20020304 |
|
| AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BAYER HEALTHCARE AG |
|
| 17Q | First examination report despatched |
Effective date: 20031127 |
|
| RBV | Designated contracting states (corrected) |
Designated state(s): DE ES FR GB IT |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): DE ES FR GB IT |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D Free format text: NOT ENGLISH |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D Free format text: GERMAN |
|
| REF | Corresponds to: |
Ref document number: 50009496 Country of ref document: DE Date of ref document: 20050317 Kind code of ref document: P |
|
| GBT | Gb: translation of ep patent filed (gb section 77(6)(a)/1977) |
Effective date: 20050414 |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2237445 Country of ref document: ES Kind code of ref document: T3 |
|
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
| ET | Fr: translation filed | ||
| 26N | No opposition filed |
Effective date: 20051110 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20060619 Year of fee payment: 7 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20060630 Year of fee payment: 7 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20060719 Year of fee payment: 7 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20060725 Year of fee payment: 7 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20060731 Year of fee payment: 7 |
|
| GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20070721 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20080201 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070721 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20080331 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070731 |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20070723 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070723 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070721 |